StockData
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc.

CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3078% above fair value
$17.58−0.96 (-5.18%)

Close on Nov 20, 2026Market cap $4.97BP/E –Yield –

Caris Life Sciences Adjusted EBITDA by Quarter

Adjusted EBITDA ($M)

Caris Life Sciences Adjusted EBITDA: $44.4M in Q3 2026, down 13.2% from a year earlier.

Latest, Q3 2026
44.4
Period ended Sep 30, 2026
Change on a year earlier
-13.2%
51.2 in Q3 2025
History
11 quarters
Since Q1 2024
Sources
7
Documents cited below

Where the Q3 2026 figure comes from

“Adjusted EBITDA | $ | 44,420 | $ | 51,167 | $ | 126,322 | $ | 31,665”

Source: SEC Form 8-K Ex 99.1 — Q3 2026 Financial Results (filed 2026-11-04) ↗

Net income (loss) adjusted to exclude interest income/expense, fair value changes on financial instruments, other income/expense (incl. debt extinguishment), taxes, D&A, and stock-based compensation.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Caris Life Sciences Adjusted EBITDA ($M), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Caris Life Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/cai/kpis/adjusted-ebitda-m

See every metric in the Caris Life Sciences KPI table. Data updated Nov 16, 2026.

See a number that looks wrong?